The coagulopathy associated with Coronavirus disease 2019 (COVID-19) leads to a thrombotic burden. To date, solely interim thromboprophylaxis guidance have been established, gaps in evidence are remaining, especially for ambulatory COVID-19 patients. We report a case COVID-19 in a patient with Glanzmann thrombasthenia, a rare platelet disorder associated with a high bleeding tendency. Our experience emphasizes the difficulty to manage such a condition, given the balance between thrombotic and bleeding tendencies, and the unavailability of evidence-based guidelines. Moreover, we detail hereinafter how patient’s bleeding disorder made COVID-19 diagnosis very difficult, thus highlighting the limits in actual SARS-CoV-2 molecular assays.